相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comprehensive characterization of the Published Kinase Inhibitor Set
Jonathan M. Elkins et al.
NATURE BIOTECHNOLOGY (2016)
Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
Adrian von Witzleben et al.
CANCER RESEARCH (2015)
YAP in MAPK pathway targeted therapy resistance
Keith T. Flaherty et al.
CELL CYCLE (2015)
The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
Shumei Song et al.
CLINICAL CANCER RESEARCH (2015)
Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses
Loic Lebellec et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
Chunbo He et al.
EMBO MOLECULAR MEDICINE (2015)
Imatinib in advanced chordoma: A retrospective case series analysis
Nadia Hindi et al.
EUROPEAN JOURNAL OF CANCER (2015)
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Assuntina G. Sacco et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Building a global consensus approach to chordoma: a position paper from the medical and patient community
Silvia Stacchiotti et al.
LANCET ONCOLOGY (2015)
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Christopher R. Heery et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
Emily Padfield et al.
FRONTIERS IN ONCOLOGY (2015)
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
Yook-Hwan Noh et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Sustained Response of a Clivus Chordoma to Erlotinib after Imatinib Failure
Aline Houessinon et al.
CASE REPORTS IN ONCOLOGY (2015)
Chordoma: an update on the pathophysiology and molecular mechanisms
Xin Sun et al.
CURRENT REVIEWS IN MUSCULOSKELETAL MEDICINE (2015)
The emerging roles of YAP and TAZ in cancer
Toshiro Moroishi et al.
NATURE REVIEWS CANCER (2015)
Durable stabilization of three chordoma cases by bevacizumab and erlotinib
T. Asklund et al.
ACTA ONCOLOGICA (2014)
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
Christina Therkildsen et al.
ACTA ONCOLOGICA (2014)
EGFR signaling and autophagy dependence for growth, survival, and therapy resistance
Barry Jutten et al.
CELL CYCLE (2014)
Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma
Girolamo Ranieri et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Seeding Collaborations to Advance Kinase Science with the GSK Published Kinase Inhibitor Set (PKIS)
David H. Drewry et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Emerging therapies for adult soft tissue sarcoma
Stefano Radaelli et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
S. Tjulandin et al.
INVESTIGATIONAL NEW DRUGS (2014)
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer
Takayasu Kurata et al.
INVESTIGATIONAL NEW DRUGS (2014)
Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma
Jason M. Davies et al.
JOURNAL OF NEUROSURGERY (2014)
Afatinib in NSCLC harbouring EGFR mutations
Filippo de Marinis et al.
LANCET ONCOLOGY (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Phenotypic screening in cancer drug discovery - past, present and future
John G. Moffat et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1
Edwin Choy et al.
PLOS ONE (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis
Shen Keren et al.
TUMOR BIOLOGY (2014)
Phase II study on lapatinib in advanced EGFR-positive chordoma
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2013)
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
D. C. Swinney
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Phenotypic screens as a renewed approach for drug discovery
Wei Zheng et al.
DRUG DISCOVERY TODAY (2013)
The Hippo pathway: regulators and regulations
Fa-Xing Yu et al.
GENES & DEVELOPMENT (2013)
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis
Zu-Yao Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?
Aaron R. Hansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Erlotinib Inhibits Growth of a Patient-Derived Chordoma Xenograft
I-Mei Siu et al.
PLOS ONE (2013)
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
Duane H. Hamilton et al.
ONCOTARGET (2013)
The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
Takamitsu Sasaki et al.
BIOMED RESEARCH INTERNATIONAL (2013)
In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype
Birgit Hotz et al.
GASTRIC CANCER (2012)
Phase II Study of Imatinib in Advanced Chordoma
Silvia Stacchiotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma
Andrew C. Nelson et al.
JOURNAL OF PATHOLOGY (2012)
Chordoma: current concepts, management, and future directions
Brian P. Walcott et al.
LANCET ONCOLOGY (2012)
Cancer Vaccines Targeting the Epithelial-Mesenchymal Transition: Tissue Distribution of Brachyury and Other Drivers of the Mesenchymal-Like Phenotype of Carcinomas
Duane H. Hamilton et al.
SEMINARS IN ONCOLOGY (2012)
Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers
Toshiyuki Matsunaga et al.
FRONTIERS IN PHARMACOLOGY (2012)
Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas
P. Smilek et al.
NEOPLASMA (2012)
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup
John C. Stellwagen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review
Simon G. Launay et al.
BMC CANCER (2011)
PET response and tumor stabilization under erlotinib and bevacizumab treatment of an intracranial lesion non-invasively diagnosed as likely chordoma
T. Asklund et al.
CLINICAL NEUROPATHOLOGY (2011)
Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target Laboratory investigation
Wesley Hsu et al.
JOURNAL OF NEUROSURGERY (2011)
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study
Nadege Presneau et al.
JOURNAL OF PATHOLOGY (2011)
The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target
Asem Shalaby et al.
JOURNAL OF PATHOLOGY (2011)
Recurrent Chromosomal Copy Number Alterations in Sporadic Chordomas
Long Phi Le et al.
PLOS ONE (2011)
An overview of the c-MET signaling pathway
Shawna Leslie Organ et al.
Therapeutic Advances in Medical Oncology (2011)
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
D. Mark Hickinson et al.
CLINICAL CANCER RESEARCH (2010)
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
Tetsuya Mitsudomi et al.
FEBS JOURNAL (2010)
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas†
Elena Tamborini et al.
NEURO-ONCOLOGY (2010)
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib
Ola Linden et al.
ACTA ONCOLOGICA (2009)
Response to erlotinib in a patient with treatment refractory chordoma
Nimit Singhal et al.
ANTI-CANCER DRUGS (2009)
Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors
Mark A. Seefeld et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
F. Gellibert et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
N. Presneau et al.
BRITISH JOURNAL OF CANCER (2009)
Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic Chordomas
Sangyeul Han et al.
CLINICAL CANCER RESEARCH (2009)
Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas
Asem A. E. Shalaby et al.
MODERN PATHOLOGY (2009)
Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue
Roberto Tirabosco et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Frequent deletion of the CDKN2A locus in chordoma:: analysis of chromosomal imbalances using array comparative genomic hybridisation
K. H. Hallor et al.
BRITISH JOURNAL OF CANCER (2008)
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas
S. Vujovic et al.
JOURNAL OF PATHOLOGY (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies
PM Weinberger et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CHI
S Scheil et al.
GENES CHROMOSOMES & CANCER (2001)
分享论文
